What is the 13F Pro Quality Score for BIOA?

13F Pro ranks BioAge Labs, Inc. (BIOA) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View BIOA's current score at https://13fpro.ai/research/BIOA (free sign-up required for the full ranking).

Where does 13F Pro source BIOA data?

All BioAge Labs, Inc. fundamentals and ownership data come directly from SEC EDGAR. BioAge Labs, Inc. files with the SEC under CIK 1709941. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is BIOA in?

BioAge Labs, Inc. (BIOA) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is BIOA research updated on 13F Pro?

BIOA's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

BioAge Labs, Inc.(BIOA)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1709941 BIOA stock profile & AI dashboard →

13F Pro Quality Score

28.6/100

Rank #2,435 of 2,879 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

97.5/100

Profitability

2.6/100

Balance Sheet

8.8/100

Earnings Quality

30.0/100

Free Cash Flow

2.3/100

Institutional Flow

95.4/100

Revenue Scale

3.2/100

Dilution Risk

2.5/100

BIOA Stock Analysis & AI Quality Score

AI stock analysis and institutional research for BioAge Labs, Inc. (BIOA), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores BIOA at 28.6/100 on a 32-signal composite quality model, placing it at rank #2,435 of 2,879 stocks — the bottom half of the AI-ranked universe. BIOA scores in the top quartile across revenue growth (97.5), institutional flow (95.4). Areas of concern include free cash flow (2.3) and profitability (2.6), which score below median versus the broader universe. Shareholder dilution risk is elevated at 2.5/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), BioAge Labs, Inc. reports quarterly revenue of $2.8M, net income of $-22.3M, free cash flow of $-24.1M. Top institutional holders of BIOA by reported 13-F value include a16z Capital Management, L.L.C., Cormorant Asset Management,, Sofinnova Ventures, based on the most recent SEC filings. BIOA trades on the Nasdaq exchange and files with the SEC under CIK 1709941. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate BIOA daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for BioAge Labs, Inc. directly from SEC EDGAR. BioAge Labs, Inc.'s 13F Pro composite quality score has ranged between 26 and 29 since 2026, currently 28.6 — a stable long-term trajectory across 8 quarterly and live scoring snapshots.

✦

Fun facts about BioAge Labs, Inc.

Quirks, history, and lore behind BIOA — the kind of stuff that makes a stock memorable.

1
The Basics
U.S. clinical-stage biopharmaceutical company · focused on aging biology · listed on Nasdaq · headquartered in Oakland, California.
2
The Numbers
A pre-revenue biotech burning cash on R&D, with a pipeline of candidates targeting age-related diseases — the kind of balance sheet where hope is the main asset.
3
The History
Founded in the 2010s, the company went public relatively recently and emerged from the growing scientific conviction that aging itself is a treatable medical condition, not just an inevitability.
4
The Secret
Its drug candidates aim to mimic or amplify the biology of exceptionally long-lived people, essentially asking: what do centenarians know that your cells don't?
5
The Lore
The company has partnered with Pfizer to advance programs in obesity and metabolic aging, giving this small biotech some very large shoulders to stand on.
6
The Giveaway
Its very name is a portmanteau of biology and age — a clinical-stage company on a mission to make getting older a thing you can actually treat, not just endure.

▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q1 2026

$2.8M

Net Income

Q1 2026

$-22.3M

Free Cash Flow

Q1 2026

$-24.1M

D/E Ratio

Q1 2026

0.00

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

$9.0MFY 2025

FY23 —FY24 $0.00FY25 $9.0M

Net Income

-13.4% YoY

$-80.6MFY 2025

FY23 $-63.9MFY24 $-71.1MFY25 $-80.6M

Operating Income

-18.7% YoY

$-92.8MFY 2025

FY23 $-48.4MFY24 $-78.2MFY25 $-92.8M

EPS (Diluted)

+66.2% YoY

$-2.24FY 2025

FY23 $-38.17FY24 $-6.63FY25 $-2.24

Total Assets

-17.7% YoY

$294.9MFY 2025

FY23 $25.9MFY24 $358.2MFY25 $294.9M

Total Debt

-81.7% YoY

$2.6MFY 2025

FY23 $14.2MFY24 $14.5MFY25 $2.6M

Op. Cash Flow

-58.4% YoY

$-81.6MFY 2025

FY23 $-37.4MFY24 $-51.5MFY25 $-81.6M

Metric	FY 2025	FY 2024	FY 2023
Revenue	$9.0M	$0.00	—
Net Income	$-80.6M -13.4%	$-71.1M -11.4%	$-63.9M
Operating Income	$-92.8M -18.7%	$-78.2M -61.6%	$-48.4M
EPS (Diluted)	$-2.24 +66.2%	$-6.63 +82.6%	$-38.17
Total Assets	$294.9M -17.7%	$358.2M +1281.9%	$25.9M
Total Debt	$2.6M -81.7%	$14.5M +2.1%	$14.2M
Operating Cash Flow	$-81.6M -58.4%	$-51.5M -37.9%	$-37.4M

AI Insight: BIOA Ratio Trends

BioAge Labs remains deeply unprofitable with ROIC deteriorating to -41.4% in Q4 2025, though Q1 2026 shows a partial sequential recovery.

• ROIC worsened from -30.0% in Q4 2024 to -41.4% in Q4 2025, a 11.4pp year-over-year deterioration.

• ROE swung from -16.5% in Q1 2025 to -38.1% in Q4 2025, reflecting accelerating net losses mid-cycle.

• Q1 2026 ROIC improved to -26.7% from -41.4% in Q4 2025, a meaningful sequential rebound of 14.7pp.

• Leverage is effectively zero: D/E fell from 0.05 in Q3 2024 to 0.00 in Q1 2026, indicating no debt burden.

⚠ Q4 2025 ROIC hit -41.4%, the worst in the dataset — monitor whether Q1 2026 recovery is sustained or a one-quarter anomaly.

⚠ OpMargin and NPM are absent throughout; lack of revenue-level visibility makes loss-driver diagnosis impossible.

⚠ Near-zero D/E preserves flexibility, but ongoing deep losses will erode equity base if cash burn continues.

Get alerted when BIOA's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for BioAge Labs, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of BIOA

a16z Capital Management, L.L.C.
$56.5M3,233,170 sh
Cormorant Asset Management, LP
$50.6M2,890,605 sh
Sofinnova Ventures Inc
$40.1M2,293,788 sh
BlackRock, Inc.
$39.7M2,267,756 sh
JANUS HENDERSON GROUP PLC
$36.6M2,094,270 sh
Octagon Capital Advisors LP
$30.6M1,748,000 sh
RA CAPITAL MANAGEMENT, L.P.
$28.9M1,650,648 sh
VANGUARD CAPITAL MANAGEMENT LLC
$23.7M1,354,906 sh
BALYASNY ASSET MANAGEMENT L.P.
$23.2M1,327,545 sh
BRAIDWELL LP
$21.0M1,200,587 sh

Fund	Value	Shares
a16z Capital Management, L.L.C.	$56.5M	3,233,170
Cormorant Asset Management, LP	$50.6M	2,890,605
Sofinnova Ventures Inc	$40.1M	2,293,788
BlackRock, Inc.	$39.7M	2,267,756
JANUS HENDERSON GROUP PLC	$36.6M	2,094,270
Octagon Capital Advisors LP	$30.6M	1,748,000
RA CAPITAL MANAGEMENT, L.P.	$28.9M	1,650,648
VANGUARD CAPITAL MANAGEMENT LLC	$23.7M	1,354,906
BALYASNY ASSET MANAGEMENT L.P.	$23.2M	1,327,545
BRAIDWELL LP	$21.0M	1,200,587

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put BIOA on your watchlist

Track score changes the day BioAge Labs, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is BIOA a good stock to buy?

13F Pro's AI-powered analysis of BioAge Labs, Inc. (BIOA) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for BIOA are available on the BIOA stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own BIOA?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling BIOA. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of BioAge Labs, Inc.'s investment landscape.